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Example of patient QA: Varian Trilogy linac with HD120 MLC, 
VMAT delivery technique (lung tumor), 15 MV beam quality, 
~6 Gy overall dose. 
Conclusions: The technology has been proven to be valuable 
for patient plan quality assurance of complex fields through 
an extensive clinical investigation considering different 
irradiation techniques. High dosimetric performance was 
achieved in the verification of therapy beams due to high 
spatial resolution, insensitivity on dose per pulse and energy 
independence. The new ionization chamber technology is 
intended to be used in future 2D detectors.  
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Purpose/Objective: Low energy proton beam could be of 
potential interest for radiation treatments of shallow lesions 
due to expected higher relative biological effectiveness (RBE) 
and sharp dose fall-off beyond target volume. We designed 
and performed output measurements for RBE using EBT3 
model GafChromicTM film. 
Materials and Methods: Figure 1.a represents experimental 
setup used to measure depth dose curve (Fig.1.b) and beam 
output using a calibrated PTW Markus ion chamber. To 
improve stability of irradiation beam (26.5 MeV protons) from 
cyclotron CS30, an aluminum cylinder was added in front of 
the beam serving as a timed shutter. As beam's energy 
decreases with depth, measurement depth was scaled using 
ratio of continuous slowing down approximation (CSDA) 
ranges at each point. Measured signal, corrected by monitor 
chamber reading, was scaled by ratio of stopping powers at a 
given depth for water and air divided by the same ratio in 
Cobalt. Output was measured at 3 mm depth in the middle of 
plateau ahead of the Bragg peak, and PDD was normalized at 
the same depth. Following the TRS398 reference dosimetry 
protocol for proton beams, output was measured in water in 
terms of Gy/nC where nC is reading of the monitor chamber. 
Once the output was known, we calibrated EBT3 film model 
for doses up to 35 Gy (Fig.1.c) by irradiating film pieces in 
Solid WaterTM at depth of 3 mm and converting depth to 
water. For RBE determination, attached breast cell cultures 
(MCF-7, MCF-12, MDA-MB-231) in 96-well plates were 
irradiated by the horizontal beam (Fig.1.d). Behind the plate, 
a piece of film was placed to monitor dose distribution during 
experiment. The MTT colorimetric dye assay was used to 
assess cell survival (proliferation inhibition) following 
irradiation. 
Results: Depending on the cyclotron current and collimator 
to surface distance (CSD), outputs ranged approximately from 
6.8 Gy/s (10 nA, 165 cm CSD) to 500 Gy/s (100 nA, 75 cm 
CSD). For each irradiated 96-well plate, a dose image was 
reconstructed (Fig.1.e) and then scaled by the measured PDD 
data. Natural Gaussian shape of the beam was used to obtain 
multiple dose points within the plate from single exposure. 
Average doses (per well) were used to construct the survival 
fraction (Fig.1.f). The average RBE of proton beam compared 
to x-ray at the 50% inhibitory dose was 1.22 (SD = 0.05), 
which was statistically higher (P = 0.02) than the 1.1 
reported for standard proton therapy. 
Conclusions: We described a radiochromic film-based dose 
monitoring system that can be used for colorimetric 
radiobiology assays with low energy proton beams. The 
relatively higher RBE would be promising for treatment of 
low laying lesions. Having a sharp dose fall-off behind the 
Bragg peak, high dose rate proton beam originating from a 
production cyclotron could further allow for dose escalation 
protocols in the case of superficial diseases or during intra-
operative radiotherapy procedures. Supported by NSTIP 11-
BIO1428-20. 
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Purpose/Objective: To investigate the feasibility of back-
projection portal dosimetry for accurate in vivo 3D 
dosimetric verification of Volumetric Modulated Arc Therapy 
(VMAT) prostate treatments by an EPID gantry angle-resolved 
data acquisition, throught the calculation of patient 
transmission. 
The novel approach is analysing data by dose volume 
histograms (DVH), that provide information on actual 
delivered dose to the tumor volume and surrounding critical 
structures. 
